CVS settles opioid case with DOJ for $315 million

CVS Health (CVS) has agreed to pay $315 million to settle a case with the U.S. Justice Department regarding the company's alleged improper distribution of opioid prescriptions. This settlement resolves claims that CVS pharmacies filled numerous invalid prescriptions, which had a significant impact on the opioid crisis in the United States. The U.S. government had accused the pharmacy chain of violating the Controlled Substances Act by improperly filling prescriptions that were not issued for a legitimate medical purpose or outside the usual course of professional practice. CVS stated that it is committed to supporting communities in combatting the opioid crisis and that this settlement does not include any admission of liability or wrongdoing by the company. By addressing this issue, CVS aims to focus on ensuring compliance and patient safety in the future. This settlement highlights the ongoing scrutiny placed on pharmacy chains and the healthcare sector regarding their role in the opioid epidemic, which is an important consideration for investors tracking regulatory impacts on the sector.